跳至主要内容
临床试验/NCT00113165
NCT00113165已完成3 期

A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures

GlaxoSmithKline149 个研究点 分布在 2 个国家目标入组 244 人开始时间: 2004年10月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
244
试验地点
149
主要终点
The efficacy of LAMICTAL extended-release therapy will be measured by the percentage change from Baseline in partial seizure frequency during the double-blind treatment phase.

研究概览

简要总结

This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures. LAMICTAL extended-release is an investigational drug. Placebo tablets look like LAMICTAL extended-release tablets but do not contain active medication. In this study, LAMICTAL extended-release or placebo tablets will be added to current seizure treatments.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
13 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

The efficacy of LAMICTAL extended-release therapy will be measured by the percentage change from Baseline in partial seizure frequency during the double-blind treatment phase.

时间窗: 24 Weeks

次要结局

  • Reduction in partial seizure frequency during portions of double-blind phase (=25%,=50%,=75%,100%). Time to 50% reduction in partial seizure frequency. Adverse events. Weight change. Health outcomes questionnaires. Population Pharmacokinetics(24 Weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (149)

Loading locations...

相似试验

Study Evaluating LAMICTAL Extended-Release Therapy... | 临床试验